Viewing Study NCT02108951

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2026-02-01 @ 10:16 PM
Study NCT ID: NCT02108951
Status: TERMINATED
Last Update Posted: 2017-10-27
First Post: 2014-04-07
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Philidelphia Positive Chronic Myeloid Leukaemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CML View
None Ph-CML View
None leukaemia View
None leukemia View
None chronic myeloid leukemia View
None chronic myeloid leukaemia View
None TKI intolerance View
None tyrosine kinase inhibitor View
None tyrosine kinase inhibitor intolerance View